
[ Mon, Mar 10th ]: MarketBeat
Despite Challenges Novo Nordisk Plans to Crush GLP-1 Competitors


🞛 This publication is a summary or evaluation of another publication 🞛 This publication contains editorial commentary or bias from the source
Novo Nordisk A/S (NYSE: NVO) has declared that its GLP-1 drugs for chronic obesity, under the brands Ozempic and Wegovy, are no longer in short supply. This caused the United States Food and Drug Administration (FDA) to take semaglutide,

Read the Full MarketBeat Article at:
[ https://www.msn.com/en-us/health/weightloss/despite-challenges-novo-nordisk-plans-to-crush-glp-1-competitors/ar-AA1ACDkz ]
Similar Health and Fitness Publications